SAB Biotherapeutics, Inc.
SABS
$1.79
$0.03992.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -2.29% | 14.78% | |||
| Gross Profit | 3.75% | -19.39% | |||
| SG&A Expenses | -28.94% | -4.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.49% | 8.07% | |||
| Operating Income | 11.50% | -10.86% | |||
| Income Before Tax | -10.10% | -41.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.10% | -41.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.10% | -41.09% | |||
| EBIT | 11.50% | -10.86% | |||
| EBITDA | 10.80% | -13.05% | |||
| EPS Basic | -9.73% | -41.02% | |||
| Normalized Basic EPS | -9.96% | -41.02% | |||
| EPS Diluted | -9.73% | -41.02% | |||
| Normalized Diluted EPS | -9.96% | -41.02% | |||
| Average Basic Shares Outstanding | 0.35% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.35% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||